How to Prevent HPV: Vaccine, Screening and Safer Sex in India

• Around 80% of sexually active adults get at least one HPV type in their lifetime, and most infections clear on their own within 1–2 years.
• Two pillars prevent almost all cervical cancer: HPV vaccination (ideally at age 9–14, before any sexual exposure) and regular cervical screening from age 30.
• Three vaccines are sold in India — Cervavac (Indian-made, Rs 2,000–3,000/dose), Gardasil 4 (Rs 3,500–4,500) and Gardasil 9 (Rs 4,000–5,500); Cervavac is now entering the free government programme for girls.
• Condoms cut HPV transmission by roughly 70% but cannot fully prevent it, because the virus can sit on skin a condom does not cover.
• Being married or having one partner does not remove the need to screen — cervical cancer in your 40s often starts from HPV picked up decades earlier.
• An HPV-positive result is common and not shameful; screening exists precisely to catch precancer years before it could become cancer.

HPV is not one virus but a family of more than 200 related viruses that infect the skin and mucous membranes. About 40 of them spread through sexual contact and infect the genital and anal area. These fall into two groups: low-risk types (mainly HPV 6 and 11) that cause around 90% of genital warts but rarely cause cancer, and high-risk types (HPV 16, 18, 31, 33, 45, 52, 58 and others) that can lead to cancer of the cervix, anus, throat, vulva, vagina or penis.

HPV 16 and 18 alone cause roughly 70% of cervical cancers worldwide — and a higher share in some Indian regional studies. But here is the most important fact: most HPV infections do nothing at all. About 90% clear on their own within two years through your normal immune response, often without you ever knowing you had it.

Cancer only becomes a risk when a high-risk type refuses to clear. Persistent infection over 10–20 years slowly drives the cell changes — graded CIN1, CIN2 and CIN3 — that can eventually become invasive cancer. That long, slow timeline is exactly what makes prevention work: a screening test can spot these precancerous cervical changes years before they turn dangerous, and treating them prevents cancer in over 90% of cases.

Cervical cancer is the dominant HPV-related cancer in India, with around 124,000 new cases and about 77,000 deaths a year (ICMR-NCRP). HPV also drives several other cancers, including vulvar and vaginal cancers, rising rates of throat (oropharyngeal) cancer linked to oral sex, and anal cancer.

HPV passes through skin-to-skin and mucosa-to-mucosa contact — almost always during sex. That includes vaginal, anal and oral sex, and even genital-to-genital contact without penetration. You do not need to have had many partners; a single partner who carries HPV can pass it on.

What does not spread HPV is reassuring to know: toilet seats, swimming pools and shared towels are essentially zero-risk, because the virus does not survive long on surfaces.

Because the virus can sit on skin that a condom does not cover — the base of the penis, the scrotum, or the vulva beyond the condom — condoms reduce but never completely remove the risk. Combined with how common HPV is in any sexually active population, this is the single biggest reason vaccination works best when given before sexual activity begins, in the 9–14 age window.

Three HPV vaccines are sold in India as of 2026, differing in how many types they cover and in price.

Cervavac is the Indian-made quadrivalent vaccine from the Serum Institute of India, approved by the DCGI in 2022. It protects against HPV types 6, 11, 16 and 18 — the same four as imported Gardasil 4 — and costs about Rs 2,000–3,000 per dose privately. Crucially, it is being added to the government's free immunisation programme for girls aged 9–14, making it the most accessible option for most Indian families.

Gardasil 4 (imported, Merck) covers the same four types and costs around Rs 3,500–4,500 per dose. Gardasil 9 covers nine types — adding 31, 33, 45, 52 and 58 — protecting against the extra high-risk strains behind roughly another 10–20% of cervical cancers; it costs about Rs 4,000–5,500 per dose and is the most comprehensive choice for families who can afford it.

Side effects are usually mild: a sore, red arm for a day or two, and sometimes a mild fever or headache. Some teenagers feel faint right after the injection, which is why you should sit or lie down for 15 minutes afterwards. Serious reactions are very rare. These vaccines contain no live virus, so they cannot give you HPV — and they do not affect fertility, a myth repeatedly disproven by the WHO, CDC, ACOG and India's own regulators. For full schedules, brand comparisons and where to book, see our detailed guide to Cervavac and Gardasil in India.

You can get HPV vaccination at paediatric and adolescent clinics, gynaecology clinics, family-medicine practices and hospital chains (Apollo, Fortis, Manipal, Cloudnine, Motherhood, Rainbow, Max), and through some diagnostic centres. Several states have begun school-based programmes for girls in standards 5–9 in partnership with ICMR and UNICEF, with free vaccination and parental consent.

The number of doses depends on the age when you start:

Even the best vaccine (Gardasil 9) covers about 90% of cancer-causing types, and most women old enough to develop cervical cancer today were never offered the vaccine in their youth. That is why screening is essential alongside vaccination. India uses three methods, and our dedicated guide to cervical cancer screening walks through each in depth.

Visual inspection with acetic acid (VIA) is the low-cost public-sector method. The cervix is swabbed with dilute vinegar, which turns precancerous areas white for the examiner to see. Trained nurses can do it with minimal equipment and give results on the spot, which makes single-visit “screen-and-treat” possible. It is free for women aged 30–65 at Ayushman Bharat Health and Wellness Centres under the NPCDCS programme.

The Pap smear collects a small sample of cervical cells to check under a microscope, graded by the Bethesda system (normal, ASCUS, LSIL, HSIL and so on). It costs roughly Rs 500–2,500 privately and is free at government hospitals. If you have never had one, our walkthrough on your first Pap smear explains exactly what to expect.

HPV DNA testing is the most sensitive method (around 90–95% for high-grade changes) and is now the preferred primary screen for women 30–65 under WHO guidance. A positive result triggers a reflex Pap or colposcopy. Because it is so sensitive, a negative result means you can safely wait five years before the next test. It costs about Rs 1,500–4,500 privately and is often free at government tertiary cancer centres. HPV self-sampling — collecting your own vaginal sample without a speculum — is expanding in India and helps women who find the internal exam difficult.

Indian guidance (FOGSI, ICMR, NPCDCS): screen women aged 30–65 every 3–5 years by Pap or VIA, or every 5 years by HPV test. Women under 30 are generally not HPV-tested, because infections at that age are common and usually clear; a Pap from age 21 every three years is the option for younger women.

Sexual habits meaningfully change your HPV risk, even though no behaviour removes it completely. The evidence on each:

Condoms cut HPV transmission by around 70% per partner and lower the risk of genital warts and cervical changes — but the virus can be on uncovered skin, so protection is partial. Use a fresh condom for every act, including oral and anal sex, putting it on before any genital contact. Our piece on how effective condoms really are covers correct use. Female condoms (FC2, about Rs 30–80 each) cover slightly more skin and are a good option too.

Dental dams — thin latex squares placed over the vulva or anus during oral sex — reduce throat acquisition of HPV. They cost roughly Rs 80–300 and are sold online; a clean piece of cling film is a less reliable improvised substitute.

Fewer partners and mutual monogamy lower your cumulative exposure, but do not protect against HPV that either partner already carries from before the relationship.

Stopping smoking matters more than most people realise: smoking weakens the immune system's ability to clear HPV and is an independent cervical cancer risk factor. Second-hand smoke counts too.

Knowing your HIV status is important because HIV makes HPV far more likely to persist and progress; HIV-positive women need yearly screening. Read more in our guides to HIV prevention for women in India and the wider picture of STI screening, symptoms and treatment.

Finally, remember the vaccine still helps even if you are already sexually active — it protects against the types you have not yet met. It is preventive, not a treatment, so it will not cure an existing infection or abnormal Pap.

For many women, an HPV-positive or abnormal Pap result is their first real encounter with HPV — and it can feel far scarier than it actually is. Start with the facts: HPV is extraordinarily common, most infections clear within 1–2 years, and almost all precancerous changes can be treated successfully long before they ever become cancer. Our guide to what an abnormal Pap smear means and the next steps breaks this down calmly.

If you are high-risk HPV-positive with a normal Pap, what happens next depends on the type. HPV 16 or 18 (the highest-risk types) usually prompts a colposcopy even with a normal Pap. For other high-risk types, the standard is a repeat HPV test in 12 months, since many clear in that window; continued positivity then leads to colposcopy.

If your Pap shows changes, management follows the grade: ASCUS with negative HPV returns to routine screening, while LSIL, HSIL, ASC-H or glandular abnormalities lead to colposcopy and biopsy. A colposcopy in India costs about Rs 1,500–4,500 privately and is free at government tertiary centres.

Treatment, when needed, is highly effective. Mild changes (CIN1) often resolve on their own and may just be watched. Higher-grade changes (CIN2–3) are usually treated by removing the affected tissue — most often a LEEP procedure — with cure rates around 90–95%. After treatment, plan on closer follow-up (yearly co-testing for three years, then less often) for up to 20–25 years.

The emotional side deserves honesty too. An HPV result is not a verdict on your character or your relationship — HPV is a near-universal background exposure, you have done nothing wrong, and the screening system is working exactly as designed. Partner testing is generally not recommended, because most infections clear and there is no treatment for symptomless HPV.

HPV affects men too, and prevention works better when partners understand their role. Men can carry and pass on HPV, develop genital warts (mostly HPV 6 and 11), and develop HPV-related cancers — throat cancer is now the most common HPV cancer in men in several countries, alongside anal and penile cancer.

Vaccinating boys aged 9–26 protects them directly and adds herd protection that lowers transmission to female partners. There is no reliable routine HPV test for men, so screening men is not recommended; visible warts can simply be diagnosed and treated when they appear.

Unlike chlamydia or HIV, HPV does not call for partner notification — a partner has very likely already been exposed, there is no treatment for symptomless infection, and testing men is not useful. Open conversation about sexual health is healthy, but an HPV diagnosis should not be framed as an accusation. For couples, sharing accurate information matters; our explainer on sexual health for married women can help start that conversation. Mutual vaccination where age-appropriate is a reasonable shared decision.

Some women carry a higher risk of persistent infection or faster progression and need more intensive prevention or surveillance:

Genital warts (condyloma acuminata) come from low-risk types HPV 6 and 11, which cause about 90% of cases. They affect roughly 1% of sexually active adults each year and, while they do not cause cancer, they can cause real distress. All three HPV vaccines cover types 6 and 11, so vaccination prevents around 90% of genital warts when given before exposure — our dedicated guide to genital warts and HPV covers them in full.

They appear as soft, fleshy, sometimes cauliflower-like growths on the vulva, vagina, cervix, perineum or perianal area — single or multiple, painless or mildly itchy. Diagnosis is usually by a doctor's visual examination.

Treatments include topical podophyllotoxin (Wartec, Condyline, about Rs 300–1,000) or imiquimod cream (Rs 500–2,500), cryotherapy with liquid nitrogen, trichloroacetic acid applied by a clinician, and electrocautery or laser for larger warts. Recurrence is common, so repeat treatment is sometimes needed.

During pregnancy, warts can grow quickly and treatment options are narrower (podophyllotoxin and imiquimod are not used); very rarely, large warts at delivery may prompt a caesarean. HPV can also cause precancerous changes of the vulva (VIN), vagina (VAIN) and anus (AIN), all of which are reduced by vaccination. For the full pathology across HPV types, see our reference on HPV types, symptoms and treatment.

HPV itself rarely causes symptoms, so most prevention happens through scheduled screening rather than waiting for warning signs. Book a gynaecologist visit if you notice any of the following — not to panic, but because they deserve evaluation:

• WHO – Human papillomavirus and cervical cancer fact sheet
• WHO – Human papillomavirus (HPV) vaccines: position paper)
• ICMR-NICPR – Cervical cancer screening and HPV in India
• CDC – HPV vaccination recommendations and safety
• ACOG – Human Papillomavirus Vaccination
• Serum Institute of India – CERVAVAC (qHPV vaccine)